Novartis India Ltd
- Market Cap ₹ 2,986 Cr.
- Current Price ₹ 1,209
- High / Low ₹ 1,275 / 750
- Stock P/E 32.0
- Book Value ₹ 331
- Dividend Yield 2.07 %
- ROCE 16.2 %
- ROE 11.6 %
- Face Value ₹ 5.00
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- The company has delivered a poor sales growth of -1.46% over past five years.
- Company has a low return on equity of 11.9% over last 3 years.
- Earnings include an other income of Rs.38.8 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE 1000
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 870 | 690 | 656 | 564 | 491 | 438 | 381 | 400 | 379 | 335 | 356 | 354 | |
| 874 | 656 | 631 | 570 | 478 | 426 | 355 | 373 | 314 | 270 | 265 | 260 | |
| Operating Profit | -4 | 34 | 25 | -6 | 12 | 12 | 27 | 27 | 65 | 65 | 91 | 94 |
| OPM % | -0% | 5% | 4% | -1% | 2% | 3% | 7% | 7% | 17% | 19% | 26% | 27% |
| 101 | 207 | 71 | 172 | 78 | 36 | 33 | -17 | 58 | 62 | 42 | 39 | |
| Interest | 0 | 0 | 1 | 6 | 2 | 6 | 8 | 5 | 2 | 1 | 1 | 1 |
| Depreciation | 4 | 3 | 4 | 3 | 3 | 13 | 12 | 10 | 6 | 3 | 2 | 2 |
| Profit before tax | 93 | 237 | 92 | 158 | 86 | 29 | 40 | -4 | 115 | 123 | 130 | 130 |
| Tax % | 15% | 16% | 38% | 50% | 40% | 65% | 48% | -3% | 10% | 31% | 23% | 28% |
| 79 | 198 | 57 | 78 | 52 | 10 | 21 | -4 | 103 | 85 | 101 | 93 | |
| EPS in Rs | 24.75 | 62.04 | 20.33 | 31.74 | 20.97 | 4.08 | 8.46 | -1.51 | 41.86 | 34.50 | 40.87 | 37.74 |
| Dividend Payout % | 40% | 16% | 49% | 32% | 48% | 245% | 118% | -663% | 113% | 72% | 61% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -6% |
| 5 Years: | -1% |
| 3 Years: | -2% |
| TTM: | -1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -7% |
| 5 Years: | 35% |
| 3 Years: | -3% |
| TTM: | -8% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 14% |
| 3 Years: | 19% |
| 1 Year: | 39% |
| Return on Equity | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 11% |
| 3 Years: | 12% |
| Last Year: | 12% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 14 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 |
| Reserves | 986 | 1,178 | 906 | 721 | 747 | 708 | 699 | 679 | 763 | 732 | 773 | 805 |
| 0 | 0 | 0 | 0 | 0 | 68 | 62 | 24 | 22 | 7 | 5 | 3 | |
| 244 | 239 | 230 | 377 | 223 | 289 | 229 | 242 | 186 | 173 | 158 | 157 | |
| Total Liabilities | 1,246 | 1,433 | 1,150 | 1,111 | 982 | 1,078 | 1,002 | 958 | 983 | 925 | 948 | 978 |
| 8 | 6 | 6 | 5 | 15 | 76 | 64 | 24 | 19 | 7 | 5 | 3 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,238 | 1,426 | 1,144 | 1,106 | 967 | 1,001 | 938 | 934 | 964 | 918 | 943 | 975 | |
| Total Assets | 1,246 | 1,433 | 1,150 | 1,111 | 982 | 1,078 | 1,002 | 958 | 983 | 925 | 948 | 978 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -60 | 57 | -41 | 161 | -194 | -23 | -69 | 39 | 45 | 113 | 75 | 47 | |
| 719 | -630 | 424 | 69 | 274 | 56 | 95 | 87 | -153 | 33 | -3 | 18 | |
| -38 | -39 | -332 | -268 | -30 | -41 | -37 | -36 | -30 | -121 | -64 | -64 | |
| Net Cash Flow | 622 | -612 | 51 | -38 | 50 | -9 | -11 | 90 | -139 | 26 | 7 | 0 |
| Free Cash Flow | -64 | 54 | -44 | 160 | -208 | -24 | -69 | 38 | 45 | 113 | 75 | 46 |
| CFO/OP | 601% | 398% | 13% | -3,503% | -1,210% | 124% | -127% | 210% | 65% | 115% | 99% | 87% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 35 | 27 | 23 | 28 | 34 | 31 | 37 | 41 | 35 | 45 | 41 | 38 |
| Inventory Days | 103 | 92 | 104 | 84 | 111 | 117 | 119 | 117 | 99 | 82 | 74 | 98 |
| Days Payable | 98 | 89 | 87 | 158 | 168 | 145 | 137 | 148 | 108 | 112 | 93 | 101 |
| Cash Conversion Cycle | 40 | 30 | 40 | -45 | -23 | 3 | 19 | 10 | 26 | 15 | 22 | 36 |
| Working Capital Days | 6 | -35 | -14 | -99 | 7 | -1 | 62 | -23 | -37 | -59 | -45 | -46 |
| ROCE % | 9% | 22% | 9% | 17% | 12% | 5% | 6% | 6% | 15% | 16% | 17% | 16% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Permanent Employees Count |
|
||||||||||
| Number of Core Strategic Brands Brands |
|||||||||||
| Rural Reach - Villages Covered (Arogya Parivar) Villages |
|||||||||||
| Reach - Healthcare Professionals / Doctors Count |
|||||||||||
| Distribution Network - Number of Distributors/Dealers Count |
|||||||||||
| Market Share - Transplant Induction Patients Percentage |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1d - Newspaper publication of the corrigendum to the Notice of Postal Ballot for the appointment of Ms. Gowree Gokhale as an Independent Director dated April 16, …
- Corrigendum To The Notice Of Postal Ballot Issued On April 16, 2026, For The Appointment Of Ms. Gowree Gokhale (DIN: 09351661) As An Independent Director. 2d
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
13 May - Intimation of Newspaper advertisement by Novartis India Limited (''The Company'') regarding the publication of Audited Financial Results of the company for the quarter and financial …
-
Integrated Financial Results For The Quarter And Financial Year Ended March 31, 2026.
12 May - Submitted audited financial statements and integrated filing for quarter and year ended March 31, 2026.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On Tuesday, May 12, 2026 To Approve The Audited Financial Results For The Quarter And The Financial Year Ended March 31, 2026.
12 May - Board approved audited Q4 and FY26 results on May 12, 2026; auditors issued unmodified opinion.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business
The company is primarily engaged in the pharmaceutical business in the area of pain management, organ transplantation, neuroscience, etc. [1]